The treatment of exudative maculopathy has completely changed following the introduction of new anti-VEGF drugs. New anti-VEGF drugs are active substance used for treating exudative maculopathy with great success. These medications can stop the disease’s development and, in some cases, even improve vision. They are injected inside the eye so that they can stop neovessels growth: this is typical of exudative maculopathy.Injection is performed as an outpatient treatment in a few minutes; anyway, this process is performed in the operatory room in order to guarantee sterility.
More than one injections is needed in a timespan of 1 to 3 months, until vision quality settles.
The current therapeutic orientation consists in perform a cycle of 3 injections (loading phase) and then intervene again only in case of loss of vision or new liquid presence when performing OCT and angiography exams.
Maculopathy therapy with new anti-VEGF drugs should be followed with extreme caution by heart patients. There is also a risk linked to intravitreal injection that is infection (endophthalmitis, about 1.5%).